HomeNews

News

FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Most cancers

The FDA has accepted an NDA for avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian most cancers.A brand new drug utility (NDA)...

Signs Related With Polycythemia Vera

Video content material above is prompted by the next:Are you able to inform us what signs a affected person may expertise with PV?What...

Chemotherapy Might Be Secure and Efficient for Pregnant Sufferers With Breast Most cancers

Chemotherapy is protected and efficient for pregnant girls with breast most cancers, with no vital distinction in long-term outcomes in comparison with non-pregnant...

Survivor’s Guilt: Asking, ‘Why Me?’

Regardless of being declared cancer-free after preliminary remedy, I grapple with survivor's guilt, questioning why my lymphoma responded to remedy whereas others didn't.

Most cancers Therapies Authorized by the FDA in December 2024

The Meals and Drug Administration in December permitted a number of new most cancers medication, together with remedies for lung, pancreatic and pores...

Hot Topics